| 排名 | 分析师 | 机构 | 行业 | 年度收益率 | 6个月收益率 | 3个月收益率 | 正收益比例 | 成分股数量 | 历史最大跌幅 | 更新日期 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 夏禹 | 国联民生 | 医药生物 | 54.42% | 5.12% | -1.98% | 20.00% | 7 | -52.01% | 2025-12-01 |
| 2 | 顾资然 | 中信证券 | 医药生物 | 54.41% | 45.22% | 49.08% | 66.67% | 7 | -1.79% | 2025-09-19 |
| 3 | 夏禹 | 国联民生 | 医药生物 | 54.40% | 47.78% | 18.62% | 20.00% | 7 | -52.01% | 2025-08-20 |
| 4 | 顾资然 | 中信证券 | 医药生物 | 54.37% | 46.58% | 35.56% | 66.67% | 6 | -1.79% | 2025-10-16 |
| 5 | 夏禹 | 国联民生 | 医药生物 | 54.37% | 53.41% | 21.98% | 20.00% | 7 | -52.01% | 2025-07-22 |
| 6 | 周豫 | 太平洋 | 医药生物 | 54.31% | 45.52% | 35.06% | 21.21% | 23 | -55.62% | 2025-08-25 |
| 7 | 唐寅灏 | 中信证券 | 医药生物 | 54.27% | 20.90% | -13.87% | 85.71% | 9 | -8.47% | 2025-11-05 |
| 8 | 夏禹 | 国联民生 | 医药生物 | 54.24% | 51.67% | 27.37% | 20.00% | 7 | -52.01% | 2025-08-13 |
| 9 | 夏禹 | 国联民生 | 医药生物 | 54.24% | 40.57% | 4.72% | 20.00% | 7 | -52.01% | 2025-08-29 |
| 10 | 唐寅灏 | 中信证券 | 医药生物 | 54.18% | 24.85% | -12.33% | 85.71% | 9 | -8.47% | 2025-10-23 |
| 11 | 唐寅灏 | 中信证券 | 医药生物 | 54.17% | 40.57% | 35.93% | 85.71% | 12 | -8.47% | 2025-06-10 |
| 12 | 顾资然 | 中信证券 | 医药生物 | 54.10% | 49.08% | 40.85% | 66.67% | 6 | -1.79% | 2025-08-11 |
| 13 | 张林晚 | 上海证券 | 医药生物 | 54.08% | 52.51% | 22.46% | -100.00% | 1 | -18.93% | 2025-09-01 |
| 14 | 周豫 | 太平洋 | 医药生物 | 54.06% | 51.57% | 40.72% | 21.21% | 23 | -55.62% | 2025-08-18 |
| 15 | 彭波 | 甬兴证券 | 医药生物 | 54.06% | 50.14% | 42.62% | 40.00% | 16 | -24.57% | 2025-09-11 |
| 16 | 韩世通 | 中信证券 | 医药生物 | 54.05% | 43.61% | 33.01% | -2.04% | 6 | -63.25% | 2025-08-29 |
| 17 | 韩世通 | 中信证券 | 医药生物 | 54.01% | 53.29% | 42.42% | -2.04% | 6 | -63.25% | 2025-08-13 |
| 18 | 周豫 | 太平洋 | 医药生物 | 54.00% | 42.79% | 18.32% | 21.21% | 23 | -55.62% | 2025-09-12 |
| 19 | 夏禹 | 国联民生 | 医药生物 | 53.97% | 53.50% | 22.71% | 20.00% | 7 | -52.01% | 2025-08-01 |
| 20 | 叶思奥 | 光大证券 | 医药生物 | 53.96% | 43.09% | 43.13% | -25.00% | 3 | -47.18% | 2025-09-15 |